SENS PubMed Publication Search
Reduction of Amyloid in the Brain and Retina After Treatment With IVIG for Mild Cognitive Impairment
Shawn Kile 1, William Au 1, Carol Parise 2, Jaideep Sohi 3, Tracy Yarbrough 3, Alan Czeszynski 4, Ken Johnson 4, Dan Redline 4, Tammy Donnel 2, Andrea Hankins 2, Kimberley Rose 1
Abstract:
Objective: To assess whether intravenous immunoglobulin (IVIG) in subjects with mild cognitive impairment (MCI) results in a reduction in amyloid in the central nervous system (CNS).
Methods: Five subjects with MCI underwent baseline Florbetapir positron emission tomography and retinal autofluorescent imaging. All were administered IVIG (Octagam 10%) at 0.4 g/kg every 14 days for a total of 5 infusions. After 3 months, standard uptake value ratio (SUVR) and amyloid retinal deposits were reassessed.
Results: Three subjects had a reduction in amyloid SUVR and all 5 subjects had a reduction in amyloid retinal deposits in at least 1 eye.
Conclusions: A short course of IVIG over 2 months removes a measurable amount of amyloid from the CNS in persons with MCI.
Methods: Five subjects with MCI underwent baseline Florbetapir positron emission tomography and retinal autofluorescent imaging. All were administered IVIG (Octagam 10%) at 0.4 g/kg every 14 days for a total of 5 infusions. After 3 months, standard uptake value ratio (SUVR) and amyloid retinal deposits were reassessed.
Results: Three subjects had a reduction in amyloid SUVR and all 5 subjects had a reduction in amyloid retinal deposits in at least 1 eye.
Conclusions: A short course of IVIG over 2 months removes a measurable amount of amyloid from the CNS in persons with MCI.
PMID: 32048858
Free Full-Text: https://journals.sagepub.com/doi/10.1177/1533317519899800
